Minerva Neurosciences (NERV) Accumulated Expenses (2013 - 2026)
Minerva Neurosciences (NERV) posted Accumulated Expenses of $355729.0 for Q1 2026, down 78.45% on a QoQ basis from $1.7 million in Q4 2025, and up 481.27% year-over-year from $61199.0 in Q1 2025.
Minerva Neurosciences (NERV) Accumulated Expenses (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Accumulated Expenses history runs 14 years deep, the most recent figure standing at $355729.0 for Q1 2026.
- Quarterly Accumulated Expenses rose 481.27% year-over-year to $355729.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $355729.0 (up 481.27% YoY) and the FY2025 annual result came in at $1.7 million, up 34.32% from the prior year.
- Accumulated Expenses was $355729.0 for Q1 2026 at Minerva Neurosciences, down from $1.7 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $3.9 million in Q3 2024 and bottomed at $47984.0 in Q1 2022.
- A 5-year average of $928849.3 and a median of $727302.0 in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Accumulated Expenses tumbled 92.98% — and 2024, when it surged 4797.56%.
- Minerva Neurosciences' Accumulated Expenses stood at $407909.0 in 2022, then jumped by 276.33% to $1.5 million in 2023, then slipped by 19.94% to $1.2 million in 2024, then soared by 34.32% to $1.7 million in 2025, then slumped by 78.45% to $355729.0 in 2026.
- Business Quant data shows NERV's Accumulated Expenses at $355729.0 in Q1 2026, $1.7 million in Q4 2025, and $1.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Minerva Neurosciences | 185.26 Mn | 185.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 355,729.00 |
| Dec 31, 2025 | 1.65 Mn |
| Sep 30, 2025 | 1.04 Mn |
| Jun 30, 2025 | 122,397.00 |
| Mar 31, 2025 | 61,199.00 |
| Dec 31, 2024 | 1.23 Mn |
| Sep 30, 2024 | 3.93 Mn |
| Jun 30, 2024 | 727,302.00 |
| Mar 31, 2024 | 363,650.00 |
| Dec 31, 2023 | 1.54 Mn |
| Sep 30, 2023 | 80,241.00 |
| Jun 30, 2023 | 806,156.00 |
| Mar 31, 2023 | 396,494.00 |
| Dec 31, 2022 | 407,909.00 |
| Sep 30, 2022 | 1.14 Mn |
| Jun 30, 2022 | 1.89 Mn |
| Mar 31, 2022 | 47,984.00 |
| Dec 31, 2021 | 965,739.00 |
| Sep 30, 2021 | 601,264.00 |
| Jun 30, 2021 | 766,522.00 |